Otsuka completes Visterra acquisition for about $430 mln
Otsuka has closed its previously announced acquisition of Visterra, a developer of antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for about $430 million in cash. Visterra's backers included Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Temasek Holdings, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.
4 September 2018•2 mins read
